About Pedro Lichtinger Waisman
Form D filings for Starton Therapeutics from 2023 to 2024 list Pedro Lichtinger Waisman as executive officer and director.
Pedro Lichtinger Waisman first appears on SEC filings in 2023.
Experience
This experience comes from SEC filings. The years are when the filings name Pedro Lichtinger Waisman in the role, so the role may have started earlier or lasted longer.
Key Colleagues at Startups
The people Pedro Lichtinger Waisman works with at each company, as listed on that company's latest Form D.
Starton Therapeutics Inc. · Form D, Oct 22, 2024
SK
Scott Kahn
Chief Financial Officer
NK
Nitin Kaushal
Director
MH
Mohamad Hussein
Director
EB
Eric Baum
Director
RW
Roy Waldron
Director
AK
Asher Chanan-Khan
Director
KA
Kenneth Anderson
Director
MD
Moses Dodo
Director
FP
Fotios Plakogiannis
Director
JO
Jamie Oliver
Executive officer